Cellular Dynamics International (NASDAQ: ICEL) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.
This is a breakdown of recent recommendations and price targets for Cellular Dynamics International and Curis, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Dynamics International||0||0||0||0||N/A|
Valuation & Earnings
This table compares Cellular Dynamics International and Curis’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellular Dynamics International||N/A||N/A||N/A||($1.94)||-8.53|
|Curis||$7.53 million||16.33||-$60.41 million||($0.40)||-1.87|
Cellular Dynamics International has higher earnings, but lower revenue than Curis. Cellular Dynamics International is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
This table compares Cellular Dynamics International and Curis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Dynamics International||-88.12%||-57.59%||-38.09%|
Insider and Institutional Ownership
55.2% of Curis shares are held by institutional investors. 4.1% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Curis beats Cellular Dynamics International on 7 of the 10 factors compared between the two stocks.
Cellular Dynamics International Company Profile
Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.
Curis Company Profile
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Receive News & Ratings for Cellular Dynamics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Dynamics International and related companies with MarketBeat.com's FREE daily email newsletter.